Dogwood Therapeutics, Inc. (DWTX) Stock Price & Analysis
Dogwood Therapeutics, Inc. (DWTX) fell 0.68% to USD 1.45 as of June 10, 2026 at 02:22 UTC, according to Nexqual real-time market data.
DWTX last closed at USD 1.46; the session ranged USD 1.42–1.51 on volume of 39,391 shares. Market capitalization is $48.76M, with a 52-week range of USD 1.28–9.5 (NCM). Source: Nexqual, June 10, 2026 at 02:22 UTC.
Key Statistics (as of June 10, 2026 at 02:22 UTC)
| Price | USD 1.45 |
|---|---|
| Change | ▼ 0.68% (down) |
| Previous Close | USD 1.46 |
| Open | USD 1.51 |
| Day Range | USD 1.42 – 1.51 |
| 52-Week Range | USD 1.28 – 9.5 |
| Volume | 39,391 shares |
| Market Cap | $48.76M |
| Exchange | NCM |
Technical Analysis (DWTX)
Nexqual's technical model rates DWTX "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 02:22 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 38.32 (neutral) |
| vs SMA50 | Below (USD 1.69) |
| MACD | -0.06 (negative) |
Analyst Ratings (DWTX)
Wall Street analysts rate DWTX "None" based on 3 analysts, with a mean price target of USD 14 (range USD 12–15), per Nexqual as of June 10, 2026 at 02:22 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 14 |
| High Target | USD 15 |
| Low Target | USD 12 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (DWTX)
| Next Earnings Date | 2026-05-14 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.15 vs est -0.2 ▲ beat |
| 2025-12-31 | USD -0.26 vs est -0.86 ▲ beat |
| 2025-09-30 | USD -8.2 vs est -1.58 ▼ miss |
| 2025-06-30 | USD -1.99 vs est -1.9 ▼ miss |
Source: Nexqual, June 10, 2026 at 02:22 UTC.
Financials & Fundamentals (DWTX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Debt / Equity | 0.22 |
| Total Cash | $6.52M |
| Total Debt | $162,604 |
Source: Nexqual, June 10, 2026 at 02:22 UTC.
Financial Health Score (DWTX)
Nexqual rates Dogwood Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 02:22 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $7M cash, no debt |
| Cash Flow | Mixed — No data |
| Efficiency | Mixed — No data |
Ownership (DWTX)
| Insider Ownership | +74.49% |
|---|---|
| Institutional Ownership | +10.97% |
| Shares Outstanding | 33.63M |
| Float | 5.07M |
| Short % of Float | +0.55% |
Source: Nexqual, June 10, 2026 at 02:22 UTC.
Leadership (DWTX)
Dogwood Therapeutics, Inc. is led by Gregory Duncan (age 60), Chairman & CEO, per Nexqual as of June 10, 2026 at 02:22 UTC.
| Chairman & CEO | Gregory Duncan (age 60) |
|---|---|
| CFO, Secretary & Treasurer | Angela Walsh (age 58) |
| Senior Vice President of Operations | Ralph D. Grosswald M.P.H. (age 56) |
| Chief Scientific Advisor | Carol Duffy |
Major Backers & Investors (DWTX)
Notable institutional backers of Dogwood Therapeutics, Inc. include Armistice Capital, LLC, Fidelity, according to Nexqual as of June 10, 2026 at 02:22 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Armistice Capital, LLC | 9.75% |
| Fidelity | 0.22% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 0.97% |
| Geode Capital | 0.24% |
Source: Nexqual, June 10, 2026 at 02:22 UTC.
From Dogwood Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-18)
Key Strengths & Strategy (as disclosed to the SEC)
- Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ALUR | Allurion Technologies Inc. | USD 0.74 | ▼ 14.7% |
| SLXN | Silexion Therapeutics Corp | USD 4.17 | ▼ 10.71% |
| NVNI | Nvni Group Limited | USD 1 | ▼ 1.96% |
| AIFF | Firefly Neuroscience, Inc. | USD 1.61 | ▲ 1.9% |
| ACON | Aclarion, Inc. | USD 3.26 | ▼ 8.68% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:22 UTC. This page is informational and not investment advice.